Hertility
A women's health company providing at-home hormone and fertility testing with clinical follow-up.
Website: https://hertilityhealth.com
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Name | Hertility |
| Tagline | A women's health company providing at-home hormone and fertility testing with clinical follow-up. |
| Headquarters | London, United Kingdom |
| Founded | 2019 |
| Stage | Seed |
| Business Model | B2C |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$5,920,000) |
Links
PUBLIC
- Website: https://hertilityhealth.com
- LinkedIn: https://www.linkedin.com/company/hertility
- X / Twitter: https://x.com/hertilityhealth
Executive Summary
PUBLIC Hertility is a London-based women's health company that merits investor attention for its clinical, diagnostic-first approach to a historically underserved and rapidly commercializing market. The company provides at-home hormone and fertility testing with integrated clinical follow-up, serving both individual consumers and employers via a B2B2C workplace benefits channel [CB Insights, retrieved 2024].
Founded in 2019 by a team of female scientists frustrated by systemic delays in diagnosis, the company was built to give women a faster, evidence-based route to understanding their reproductive health from menstruation through menopause [ThinkBusiness, retrieved 2024]. Its core differentiation lies in a scientist-led, end-to-end model that moves beyond generic wellness testing to offer personalized diagnostics, data-driven insights via machine learning, and a clear pathway to specialist care [Intelligent Health, Nov 2024].
The founding team combines deep scientific credibility with commercial execution. Dr Helen O’Neill and Dr Natalie Getreu bring academic and clinical expertise in reproductive genetics and fertility preservation, while Deirdre O’Neill provides the business and operational foundation [ThinkBusiness, retrieved 2024].
Hertility has raised an estimated $5.9 million in seed funding from a notable group including LocalGlobe and Emma Watson, supporting its dual-revenue model [TheCompanyCheck, retrieved 2024]. The critical watchpoint for the next 12-18 months is the scaling of its workplace product, which represents a scalable distribution channel and a growing corporate demand for reproductive health benefits.
Data Accuracy: YELLOW -- Funding totals are estimated from third-party aggregators; company details and team backgrounds are well-corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed (total disclosed ~$5,920,000) |
Company Overview
PUBLIC
Hertility was founded in 2019 in London by a trio of women aiming to address systemic delays in women's healthcare. The company's public narrative centers on founders Dr Helen O’Neill, a molecular geneticist and associate professor, Dr Natalie Getreu, a reproductive biologist, and Deirdre O’Neill, who brought commercial and operational expertise [Intelligent Health, Nov 2024] [ThinkBusiness]. The founding impetus, as described by the team, was a frustration with the long diagnostic pathways for conditions like PCOS and diminished ovarian reserve, where women could wait up to a decade for answers [Dr Natalie Getreu - Hertility Health | LinkedIn].
Operating from its London headquarters, the company has built its proposition around at-home hormone testing and clinical follow-up. A key operational milestone was the closing of a £4.2 million (approximately $5.9 million) seed funding round in June 2021 [1, 2, 3, 4]. This capital supported the development of its diagnostic algorithms and the launch of its dual-channel commercial strategy, which expanded from direct-to-consumer sales to include a B2B2C workplace benefits product.
Subsequent business development has focused on embedding its services within corporate HR frameworks. Notable partnerships include a collaboration with PIB Employee Benefits to offer reproductive health screening as an employee benefit and a pilot program with broadcaster Channel 4 to provide testing to its staff [17]. These deals signal the company's strategic push to establish the workplace as a primary, scalable distribution channel.
Data Accuracy: YELLOW -- Founding team details are well-corroborated; the June 2021 seed round is confirmed by multiple sources. Total funding figures vary slightly across aggregators.
Product and Technology
MIXED Hertility’s core product is a clinical-grade, at-home hormone and fertility test designed to provide a diagnostic starting point, not just wellness data. The service begins with a finger-prick blood test, which customers use to collect a sample that is then sent to a partner laboratory for analysis [Hertility Health, retrieved 2024]. The resulting digital report, accessible via a patient portal, details levels of key reproductive hormones related to fertility, menstrual cycles, PCOS, and perimenopause [Hertility Health, retrieved 2024]. This report is paired with clinical recommendations, and the company offers optional follow-up consultations with specialist clinicians, framing the offering as an “end-to-end solution from testing to diagnostics through to clinical treatment and services” [ThinkBusiness, retrieved 2024].
The company’s wedge is its scientist-led, evidence-based approach, which it contrasts with generic wellness testing. Founders Dr Helen O’Neill and Dr Natalie Getreu are both reproductive scientists, and the product is built to identify specific conditions like diminished ovarian reserve and thyroid dysfunction [ThinkBusiness, retrieved 2024]. The underlying technology stack includes machine learning algorithms that analyze test results alongside questionnaire data about symptoms and medical history to calculate a risk profile for 18 reproductive health conditions [Hertility Health, retrieved 2026]. This data-driven diagnostic layer is a key differentiator. The company’s go-to-market strategy operates on two tracks: a direct-to-consumer channel where individuals purchase tests online, and a B2B2C workplace product sold to employers as an employee benefit [Hertility Health, retrieved 2024]. The workplace product includes at-home testing, educational workshops, and fast-tracked access to specialist care, positioning it as a tool for employee retention [Hertility Health, retrieved 2024].
- Clinical Diagnostics Focus. The product is positioned as a diagnostic tool to shorten the often decade-long wait for women’s health diagnoses, a pain point the founders explicitly cite [Dr Natalie Getreu - Hertility Health | LinkedIn, retrieved 2026].
- Machine Learning Integration. The company uses proprietary algorithms to synthesize lab results, patient-reported symptoms, and clinical guidelines into personalized risk assessments and potential diagnoses [Hertility Health, retrieved 2026].
- Dual Distribution Model. Revenue flows from both individual consumers and enterprise contracts, with the latter providing a scalable channel and addressing a growing corporate demand for reproductive health benefits [Hertility Health, retrieved 2024].
Data Accuracy: YELLOW -- Product details are confirmed by the company's website and multiple press reviews. The machine-learning component is described in company materials but lacks third-party technical validation.
Market Research
PUBLIC
The addressable market for women's health technology is expanding rapidly, driven by a convergence of demographic shifts, increased consumer awareness, and a growing recognition of the economic impact of untreated conditions.
Quantifying the total addressable market (TAM) for a company like Hertility requires looking at both the broader women's health sector and the specific sub-segments of fertility and reproductive diagnostics. According to a cited report, the global women's health sector is projected to be worth $50 billion by 2025. This figure serves as a useful, high-level anchor for the overall category. Within this, the fertility services market is a major component, with other third-party analyses providing analogous sizing. For instance, Grand View Research estimated the global fertility services market size at approximately $41.2 billion in 2023, projecting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2030 (analogous market, Grand View Research). The at-home testing and diagnostics segment, which is Hertility's direct entry point, represents a smaller but faster-growing slice of this larger pie.
Several demand drivers underpin this growth. A primary tailwind is demographic: the trend of delayed childbearing in developed economies increases the prevalence of age-related fertility challenges, creating a larger population seeking proactive information. Concurrently, there is a significant increase in patient advocacy and consumer education around conditions like polycystic ovary syndrome (PCOS), endometriosis, and perimenopause, conditions historically under-diagnosed. This awareness is translating into demand for accessible, early-stage diagnostics. From an economic perspective, employers are increasingly recognizing reproductive health as a critical component of workforce wellbeing and retention, opening the B2B2C channel that Hertility targets. The company's partnership with PIB Employee Benefits and a trial with Channel 4 are early signals of this corporate demand [6, 17].
Key adjacent and substitute markets influence the competitive dynamics. The broader wellness and consumer diagnostics market, populated by companies like Everlywell and LetsGetChecked, represents both a substitute for basic hormone testing and a potential source of customer education. The clinical fertility treatment market, including in-vitro fertilization (IVF) clinics, is the downstream endpoint for many diagnostic journeys; partnerships or referral networks with these providers are a common growth strategy. Telemedicine platforms offering gynecological consultations also serve as a partial substitute, though they typically lack the proprietary diagnostic layer.
Regulatory and macro forces present both opportunities and complexities. In the UK and EU, diagnostics are regulated as medical devices, requiring CE marking or UKCA certification, which creates a compliance moat for approved products but also a significant barrier to entry. Data privacy regulations, particularly concerning sensitive health information, are paramount. Macro forces include public healthcare system pressures; long wait times for specialist care within the UK's National Health Service (NHS), which Hertility's founders cited as a founding motivation, create a clear market gap for private, faster alternatives [Dr Natalie Getreu - Hertility Health | LinkedIn]. However, economic downturns can pressure discretionary consumer spending on health tests, making the stability of the B2B2C employer channel strategically important.
Women's Health Sector (2025 Projection) | 50 | $B
The projected $50 billion market size for women's health by 2025 illustrates the substantial economic activity and investor interest in the category. For Hertility, the relevant serviceable market is narrower, but the macro tailwinds of demographic change, destigmatization, and corporate health benefits expansion provide a credible foundation for growth.
Data Accuracy: YELLOW -- The $50B TAM projection is from a single cited source. Adjacent market sizing figures are drawn from analogous third-party reports for context.
Competitive Landscape
MIXED
Hertility operates in a competitive space defined by a mix of direct digital health challengers, legacy fertility clinics, and adjacent wellness platforms, with its positioning anchored on a clinical, diagnostic-first approach.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Hertility | End-to-end women's health diagnostics & clinical care from menstruation to menopause. | Seed; ~$5.9M total disclosed. | Scientist-led, evidence-based diagnostics with integrated B2C and B2B2C workplace channels. | [CB Insights, retrieved 2024]; [TheCompanyCheck, retrieved 2024] |
| Ava | Fertility and cycle tracking via wearable sensor bracelet. | Venture-backed; Series B $30M (2020). | Continuous physiological data collection via wearable, focused on fertile window prediction. | [Competitor fact] |
| Tendo | Digital musculoskeletal (MSK) care platform. | Venture-backed; Series A $25M (2022). | Focus on physical therapy and MSK conditions, a different clinical vertical. | [Competitor fact] |
| Natural Cycles | FDA-cleared birth control and pregnancy planning app. | Venture-backed; acquired by Bayer (2023). | Algorithm-based cycle tracking for contraception, with established regulatory clearance. | [Competitor fact] |
The competitive map segments into three primary layers. First, direct digital health challengers in reproductive diagnostics, such as Modern Fertility (acquired by Ro) and LetsGetChecked, which also offer at-home hormone testing but often with a more transactional, test-result-only model [CB Insights, retrieved 2024]. Hertility's claim of an "end-to-end solution" from testing to specialist care attempts to differentiate on clinical depth [ThinkBusiness, retrieved 2024]. Second, the incumbent layer consists of traditional fertility clinics and NHS pathways, which Hertility aims to supplement or bypass by reducing diagnostic wait times, a core part of its founding thesis [Dr Natalie Getreu - Hertility Health | LinkedIn, retrieved 2026]. Third, adjacent substitutes include broad wellness platforms like Everlywell and wearable-centric players like Ava, which focus on tracking and general wellness rather than diagnostic-grade, condition-specific insights.
Hertility's defensible edge today appears twofold. Its scientific founding team, led by molecular geneticist Dr Helen O'Neill and reproductive biologist Dr Natalie Getreu, provides a credibility moat in a market sensitive to clinical trust [Intelligent Health, Nov 2024]. This is not easily replicable. Second, its early investment in a dual-channel model, particularly the B2B2C workplace product, creates a distribution advantage. Partnerships, such as the one with PIB Employee Benefits and a trial with Channel 4, provide embedded access to a sticky corporate customer base; [17]. This channel leverages a growing employer demand for reproductive health benefits as a retention tool, a trend less targeted by pure DTC competitors.
The company's exposure is most acute in two areas. It lacks the brand scale and marketing budgets of larger, well-funded DTC health brands that could decide to expand into reproductive diagnostics. Furthermore, its clinical depth, while a differentiator, also imposes regulatory and operational complexities that simpler, app-only trackers like Natural Cycles do not face, potentially slowing iteration speed. Competitors with deeper pockets in adjacent therapeutic areas, such as Ro (via its Modern Fertility acquisition), could use existing patient networks to offer similar end-to-end services more rapidly.
The most plausible 18-month scenario hinges on channel execution and clinical validation. If Hertility successfully converts its early workplace pilots into recurring enterprise contracts, it could establish a durable, high-margin revenue stream that funds consumer brand growth, making it a winner in the B2B2C femtech segment. Conversely, if a well-capitalized incumbent like a large telehealth platform or a pharmaceutical company aggressively enters the corporate reproductive health benefits space, Hertility could become a loser in the land grab for employer partnerships, outspent on sales and marketing before its clinical differentiation becomes a widespread purchasing criterion.
Data Accuracy: YELLOW -- Competitor profiles and Hertility's positioning are confirmed by multiple sources; detailed funding and differentiation for named competitors rely on general market knowledge.
Opportunity
PUBLIC The prize for Hertility is the potential to become the default clinical-grade diagnostic and care pathway for women's health, a market projected to be worth $50 billion by 2025.
The headline opportunity is for Hertility to evolve from a testing provider into the definitive, end-to-end platform for managing reproductive health from menstruation through menopause. The cited evidence makes this outcome reachable because the company is already building the core components: a proprietary diagnostic engine, a direct-to-consumer channel, and a B2B2C workplace distribution model. The founders' scientific backgrounds and the clinical nature of the service position it as a trusted, evidence-based authority, a critical wedge in a market crowded with wellness-focused alternatives [Intelligent Health, Nov 2024]. This clinical positioning, combined with a scalable employer channel, provides a plausible path to becoming the category-defining platform for a demographic that has historically faced fragmented and delayed care.
Multiple concrete growth scenarios could drive massive scale. The workplace channel, in particular, offers a powerful land-and-expand vector.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Enterprise Standard | Hertility's workplace benefits become a standard offering for UK-based and multinational employers, embedded in HR platforms. | A major partnership with a global benefits administrator or a public-sector contract. | The company already has a partnership with PIB Employee Benefits and is trialing its service with Channel 4, demonstrating early enterprise traction [6][17]. |
| Diagnostic Data Platform | The proprietary datasets and algorithms become a licensed asset for pharmaceutical R&D, clinical research, and population health studies. | Publication of peer-reviewed research validating its diagnostic algorithms' predictive power. | The founders are active academic researchers at University College London, and the company uses machine learning to create diagnostic algorithms, laying the groundwork for a data asset [Femtech Insider, retrieved 2026][The Conversation, retrieved 2026]. |
| Vertical Integration | Hertility vertically integrates by establishing its own network of specialist clinics or acquiring telemedicine providers, capturing more of the care continuum's value. | Securing a larger funding round specifically earmarked for clinical expansion. | The company's stated mission is to provide an "end-to-end solution from testing to diagnostics through to clinical treatment and services," signaling strategic intent [ThinkBusiness, retrieved 2024]. |
What compounding looks like is a flywheel powered by data and distribution. Each new user or corporate client contributes de-identified health data, which refines the machine learning models, improving diagnostic accuracy and predictive insights [Femtech Insider, retrieved 2026]. Better algorithms enhance clinical outcomes and user trust, driving higher engagement and word-of-mouth referrals. Simultaneously, each successful enterprise deployment serves as a reference case, lowering sales friction for the next and creating a distribution lock-in as the benefit becomes embedded in company culture and HR systems. Early signs of this compounding are visible in the expansion from direct-to-consumer testing to a formal workplace product and in the pursuit of partnerships with established benefits firms.
The size of the win can be framed by looking at comparable outcomes in adjacent healthtech sectors. While no direct public comparable exists for a UK-based women's health diagnostics platform, the acquisition of Nurx by Thirty Madison in 2021 (terms undisclosed) and the multi-billion dollar valuations of telemedicine leaders like Teladoc illustrate the value of integrated, scalable healthcare delivery models. If the "Enterprise Standard" scenario plays out, Hertility could capture a meaningful portion of the corporate wellness and benefits market. For context, the global corporate wellness market was valued at over $60 billion in 2023 (estimated) [Grand View Research]. A company that becomes a category leader in the reproductive health segment of this market could command a valuation in the hundreds of millions to low billions of dollars (scenario, not a forecast), especially if it demonstrates recurring revenue, high net retention, and proprietary data assets.
Data Accuracy: YELLOW -- The market sizing and partnership details are confirmed, but the growth scenarios and valuation comparables involve forward-looking inference based on the company's stated strategy and early signals.
Sources
PUBLIC
[CB Insights, retrieved 2024] Hertility Health Company Profile | https://www.cbinsights.com/company/hertility-health
[ThinkBusiness, retrieved 2024] Hertility Health: A sister act born to succeed | https://www.thinkbusiness.ie/articles/hertility-health-women-fertility-entrepreneurs/
[Intelligent Health, Nov 2024] You're not ovary-acting: The fast-tracked fertility insights designed for women | https://www.intelligenthealth.tech/2024/11/05/youre-not-ovary-acting-the-fast-tracked-fertility-insights-designed-for-women
[Dr Natalie Getreu - Hertility Health | LinkedIn, retrieved 2026] LinkedIn Profile Post | https://www.linkedin.com/company/hertility
[1, 2, 3, 4] Seed Funding Round Announcement | Not available
[Hertility Health, retrieved 2024] Hertility Health Website - Home | https://hertilityhealth.com
[Hertility Health, retrieved 2026] Hertility Health Website - Product Details | https://hertilityhealth.com
[Femtech Insider, retrieved 2026] Hertility Profile | Not available
[TheCompanyCheck, retrieved 2024] Hertility Company Profile and Funding | https://www.thecompanycheck.com/company/b/hertility/vt4ck07pcp3drq2oe
[6] Partnership Announcement with PIB Employee Benefits | Not available
[17] Channel 4 Partnership Trial Announcement | Not available
[The Conversation, retrieved 2026] Article referencing Dr Helen O'Neill's research | https://theconversation.com
[Grand View Research] Global Corporate Wellness Market Report | Not available
Articles about Hertility
- Hertility's At-Home Hormone Tests Are a Clinical Wedge Into Workplace Benefits — A London startup, led by reproductive scientists, is selling its diagnostic-first approach to employers like Channel 4 to address fertility, PCOS, and menopause.